IBSA
17.3.2022 15:42:11 CET | Business Wire | Press release
Challenge, resilience, courage, nature, innovation. These are the keywords that characterise Sailing into the Future. Together , the new international project that sees IBSA (Institut Biochimique SA) the protagonist of a new three-year enterprise, which starts in 2022, albeit with a long-term vision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005863/en/
“The project we are launching today is a real sporting endeavour, which sees us compete in some of the world’s most prestigious and challenging regattas”, stated Arturo Licenziati, President, CEO and Founder of IBSA . “This new project, however, is not only an ocean crossing, but also an opportunity to tell the values of IBSA, increasing its visibility around the world. In fact, IBSA is today an international company that maintains a vision that is always aimed at the future and ready to face challenges that go well beyond the therapeutic and personal care areas ”.
Founded in 1945 and headquartered in Lugano (Switzerland), IBSA is a leading scientific, economic and industrial reality in the pharmaceutical sector, thanks to the design outlined by Arturo Licenziati. A multinational company employing 2,000 people – including headquarters, subsidiaries and production sites – IBSA is present with its products in over 90 countries on 5 continents, with 16 subsidiaries located in Europe, China and the United States and with a turnover of over CHF 700 million.
“Innovating by keeping people at the core of our ecosystem, without ever setting limits: those are the horizons of the IBSA Group, which has always been inspired by the desire to go further ”, explained Licenziati . “ Sailing into the future. Together is a metaphor for our corporate history, but also a wish to grow and change, to find new means to offer health, well-being and new perspectives for the communities within which we operate, through social and environmental sustainability ”.
The project Sailing into the Future. Together engaged a team of great experience and sporting talent, involved right from the design and building phase of an innovative Class40 boat that will be led by Alberto Bona , the skipper who has been entrusted with the task of transforming this undertaking into a success.
“The Route du Rhum is the first stage of a three-year project: it’s one of the most challenging solo regattas in the world, as well as one of the most popular events in international ocean sailing. The project relies on a competent and greatly experienced team, while the conceptual design of the boat and its construction are entrusted to a successful duo: thus, we have all the credentials to put a winning boat in the water. The further challenge will be to make the most of the time available after the July launch, and carry out the in-water test part to make it reliable and performing ”, commented Alberto Bona . “Naturally, I thank our sponsor IBSA, with which I share the taste for the challenge, for continuous improvement, and the desire to break through new horizons. IBSA has chosen sailing to represent strength, determination, innovation, but also to raise awareness about a greater respect for nature, with a view to sustainability ”.
Beyond sport, and in a broader perspective, sailing is part of a path that brings the Company ever closer to the topic of sustainability , promoting respect for nature and the environment, but also to a new sensitivity and awareness about issues of collective responsibility , with activities in favour of people in difficulty or with disabilities.
“As part of this project, we decided to be a partner of some nautical clubs, in order to support inclusive sailing initiatives. We started a collaboration with the Yacht Club of Punta Ala (GR), to which we donated two boats for disabled children, to involve them in experiences in close contact with the sea, enabling them to navigate with accessible boats and compete in integrated races ”, explained Giorgio Pisani, Vice President Southern Europe and Project Leader . “The goal is to create an actual inclusion of the disabled on the competition field, promoting social integration as well as opportunities for dialogue, interaction and mutual understanding, thus helping break down barriers and differences ”.
The Company will also receive a prize during the award ceremony of the first edition (2022) of the Sport for Nature Awards – to be held today, March 17, 2022 – an event that aims to celebrate the “sport with a green soul”.
The award Azienda per il sociale: IBSA per la vela inclusiva (“Company for social initiatives: IBSA for inclusive sailing”) will be assigned precisely for raising awareness in favour of social and environmental sustainability through the values of sport, and in particular of sailing, as a means for social inclusion.
To narrate all the phases of the project Sailing into the Future. Together and accompany its development, the new website www.ibsasailing.com was created, also available in Italian and French . From here, it will be possible to follow the journey of skipper Alberto Bona, find out more about the Route du Rhum , the team and the new Class40 boat, that will set sail on November 6 from Saint-Malo, headed towards the island of Guadeloupe. In addition, the site will host photo and video content and news relating to IBSA’s social responsibility initiatives.
IBSA
IBSA (Institut Biochimique SA) is a multinational pharmaceutical Swiss Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 16 subsidiaries located in Europe, China and the United States. The company has a consolidated turnover of over 700 million Swiss francs, and employs 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents and others in development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardio-metabolic, respiratory, consumer health. It is also one of the four largest operators worldwide in the area of Reproductive Medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on 4 pillars: Person, Innovation, Quality and Responsibility.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005863/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom